BOOSTB4Project ID: 681045
Boost Brittle Bones Before Birth
Total cost:EUR 8 378 755,75
EU contribution:EUR 6 608 754,50
Call for proposal:H2020-PHC-2015-single-stage_RTDSee other projects for this call
Funding scheme:RIA - Research and Innovation action
Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal mesenchymal stem cells (MSC) is a promising approach for treatment of OI. We receive regular requests for MSC transplantation from patients and their physicians; patient organisations support our approach.
The principal objective of the BOOSTB4 project is to conduct a Phase I/II clinical trial of the safety and efficacy of pre- and/or postnatal MSC transplantation in the severest forms of OI (type III, severe type IV). Transplantation before birth at the onset of disease should lead to greater efficacy and engraftment with less rejection than transplantation after birth. Postnatal transplantation will be evaluated in cases where prenatal diagnosis was not made. The trial’s primary outcome is safety; secondary outcomes relate to efficacy (fracture frequency, growth, bone mineral density and quality of life). All patients will undergo molecular diagnosis to confirm OI before inclusion in the trial. Non-invasive prenatal diagnosis will be developed and validated.
The BOOSTB4 consortium is led by experts in MSC, prenatal therapy and OI at the Karolinska Institutet (KI), which will also lead the international multicentre trial; five additional EU centres of excellence are included. Ethical and regulatory applications are underway to conduct this clinical trial. These are facilitated by the ethical and regulatory approvals for prenatal MSC transplantation in 10 cases of OI that have already been granted at KI.
Successful prenatal transplantation represents a major step forward in the management of patients with severe OI, and beyond, to a range of other inherited birth defects.
EU contribution: EUR 1 827 061,50
Nobels Vag 5
EU contribution: EUR 648 543,75
WC1E 6BT LONDON
EU contribution: EUR 568 656,25
2333 ZA LEIDEN
EU contribution: EUR 703 132,50
EU contribution: EUR 1 410 493,25
Great Omond Street
WC1N 3JH LONDON
EU contribution: EUR 241 156
EU contribution: EUR 549 781,25
141 57 Huddinge
EU contribution: EUR 106 000
413 46 GOTEBORG
EU contribution: EUR 121 093,75
EU contribution: EUR 281 000
Tower House, Lucy Tower Street
LN1 1XW LINCOLN
EU contribution: EUR 50 000
LE1 7RH LEICESTER
EU contribution: EUR 101 836,25
3584 CX UTRECHT